Neoadjuvant Therapy in HER2-Positive Breast Cancer

Slides:

Advertisements

Similar presentations

Breast Cancer in Pregnancy

Advertisements

Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.

HIGHLIGHTS IN THE MANAGEMENT OF BREAST CANCER

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

Gianni L et al. Proc SABCS 2012;Abstract GS6-7.

Assistant Professor of Medicine Dana-Farber Cancer Institute

Radical Mastectomy is no longer the standard Improved adjuvant and neoadjuvant therapy Chemotherapy Endocrine therapy Radiation treatment Reconstruction.

Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.

Terapia Neoadiuvante Revisione delle evidenze scientifiche

Baselga J et al. Proc SABCS 2010;Abstract S3-3.

Case Discussion. Case #1 64 year-old postmenopausal, no PMHx Routine MMG: 2cm nodule in RUQ, with microcalcifications Biopsy: IDC grade 2 with areas of.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB (HER2-Positive) and CALGB.

Neoadjuvant Therapy for HER2+ Disease

Az Ospedaliero Universitaria di Ferrara

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

The Patient Experience With Systemic Lupus Erythematosus

The Nurse View: Management of Pancreatic Cancer

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.

OPTIMIZING NEOADJUVANT/ADJUVANT TREATMENT OPTIONS IN PATIENTS WITH BREAST CANCER DR LASEBIKAN NWAMAKA RADIATION AND CLINICAL ONCOLOGIST UNTH.

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Metastatic HER2+ Breast Cancer: Resistance

NOACs for Cancer-Associated Thrombosis:

The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.

Chronic Hepatitis C Virus Infection

Neoadjuvant Therapy for HER2-Positive Breast Cancer

Perspectives on Triple-Negative Breast Cancer

Her2-positive breast cancer: updating current best practice

The Genomics of Cancer and Molecular Testing:

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Optimizing Outcomes in the Management of GIST

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Optimizing Patient Outcomes in IBD

Clinical Considerations in Evidence-based Management of GIST

Jones SE et al. SABCS 2009;Abstract 5082.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

Treatment of HR+ Breast Cancer: A Clinical Update

Untch M et al. Proc SABCS 2010;Abstract P

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Optimizing Neoadjuvant Treatment for Primary Breast Cancer

Innovations in Home Care

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Best Practices in Lymph Node Mapping and Localization: Melanoma

Key Questions for nAMD Treatment Success

The Road to Quality Improvement in HER2-Positive Breast Cancer

The Burden of Psoriasis:

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

New Paradigms in HR-Positive Advanced Breast Cancer

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

Clinical Considerations in Evidence-based Management of GIST

Targeting IL-23 for Therapeutic Longevity in Psoriasis

PAH Pathways: What Do the Data Tell Us?”

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.

Evaluating the Totality of Evidence

Clinical Focus.

Next-Generation Sequencing and ctDNA

Exploring the Use of Adeno-Associated Virus for Gene Therapy

My PAH Patient.

Uncovering the Right Sequence

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

Neoadjuvant Therapy in HER2-Positive Breast Cancer

HER2-Positive Breast Cancer: Introduction

HER2-Targeted Therapy

Case Study Discussion

Why Administer Preoperative Therapy?

NAT for Breast Cancer

Breast Preservation Rates by Tumor Size: NCDB Results

Subtype and Rates of BCS

NAT for ILC

Impact of NAT on Breast Conservation Rates (HER2+ and TNBC)

Individual Patient Relationship of pCR With Disease Outcomes

Use of Neoadjuvant Paradigm in Clinical Research

NeoSphere Trial Neoadjuvant Pertuzumab and Trastuzumab

Lapatinib in Clinical Trial Studies

NeoSphere Results

KRISTINE/TRIO-021 T-DM1 + Pertuzumab vs TCH + Pertuzumab in HER2+ EBC

KRISTINE/TRIO-021 Results

KRISTINE/TRIO-021 Results (cont)

Sentinel Lymph Node Biopsy After NAC in Node-Positive Patients

Case Study Discussion Treatment

Barriers and Challenges to Management of Patients With Early-Stage HER2 Breast Cancer

Multidisciplinary Team Management for Breast Cancer

Key Takeaways Optimal Management of Patients With Early-Stage HER2 Breast Cancer

Abbreviations

Abbreviations (cont)